Marie-Claire Maroun

St. John's Medical Center, Jackson, Wyoming, United States

Are you Marie-Claire Maroun?

Claim your profile

Publications (1)1.18 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: There is increasing frequency and severity of disease due to Clostridium difficile infection (CDI). In addition, failure of initial antibiotic therapy is increasing. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARBs) may have local and systemic anti-inflammatory properties to reduce severity of disease in CDI. We performed a retrospective study of 306 patients with CDI over 23 months at a single center in Detroit, Michigan. Patient outcomes (death, death due to CDAD and relapse rates) were compared based on the use of ACEI or ARB during an episode of CDI. A total of 116 (37.9%) patients received an ACEI/ARB and 190 (62.1%) did not. The groups were similar except ACEI/ARB patients were older (71.9 vs. 64.3, P<0.0005) and had a higher frequency of congestive heart failure (50.9% vs. 30.2%, P<0.0005) and chronic obstructive pulmonary diseases (44.8% vs. 30.2%, P<0.010). ACEI/ARB patients had lower overall mortality rates (9.5% vs. 23.3%, P<0.002) as well as mortality due to CDI (2.6% vs. 8.6%, P<0.036). The rate of CDI relapse was not significantly different between the groups (5.2% in ACEI/ARB vs. 10.0%, P=0.135). Logistic regression analysis demonstrated that ACEI/ARB use was associated with lower overall mortality rate (OR 0.26; 95% CI, 0.12-0.55) and mortality due to CDI (OR 0.29; 95% CI, 0.08-1.02). Our findings suggest that ACEI/ARBs may have a role as an adjuvant therapy to antibiotics in patients with CDI. Prospective studies are needed to confirm these results.
    Medical Hypotheses 03/2011; 76(6):813-5. · 1.18 Impact Factor

Publication Stats

2 Citations
1.18 Total Impact Points

Top Journals

Institutions

  • 2011
    • St. John's Medical Center
      Jackson, Wyoming, United States